Organon Acquired by Sun Pharma | Healthcare M&A Deal

Sun Pharma has acquired Organon, a dermatology business in the United States, for $11.75 billion. Sun Pharma acquisitions are aimed at expanding dermatology capabilities through the Organon acquisition, leveraging Organon’s established portfolio of women’s health and specialty medicines with a dermatology focus. The merger acquisition supports broader healthcare M&A strategy by strengthening product development and commercialization in key therapeutic areas. This strategic acquisition is structured as a merger acquisition, announced at $11.75 billion, and is expected to close subject to customary regulatory approvals and other closing conditions.